PA Capital’s Bristol-Myers Squibb BMY Stock Holding History

PA Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,200	Closed	-$188K	–	180
2020 Q2	$188K	Buy	+3,200	New	+$191K	0.14%	150

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

PA Capital's BMY Position: Q3 2020 in Review

PA Capital increased its Bristol-Myers Squibb (BMY) stake by 29% in Q3 2020, buying an estimated $245K and bringing the position to 17,926 shares worth $1.08M. The position accounts for 0.76% of the portfolio, ranked #41.

PA Capital first reported a position in BMY in Q1 2019 and has held it in 7 quarters since. 2,214 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

PA Capital held 17,926 shares of Bristol-Myers Squibb worth $1.08M as of Q3 2020.
PA Capital bought 4,075 Bristol-Myers Squibb shares in Q3 2020, an estimated $245K.
Bristol-Myers Squibb made up 0.76% of PA Capital's portfolio in Q3 2020, its #41 holding.
PA Capital first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 7 quarters since.
2,214 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.